Navigation Links
Study finds women used 30 percent less analgesia during labor when self-administered
Date:2/10/2011

SAN FRANCISCO (February 10, 2011) In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting , in San Francisco, researchers will present findings that show that when women administer their own patient-controlled epidural analgesia (PCEA) instead of getting a continuous epidural infusion (CEI) they used less analgesic, but reported similar levels of satisfaction.

Women often receive a continuous epidural infusion of analgesic during labor. This can lead to prolonged labor and an increase in assisted vaginal delivery. Several pain management studies have been done to begin looking at how much analgesia women use and what their pain experience is like when they are able to administer it themselves.

"We conducted the first double blind study, excluding inductions and including only women who were delivering for the first time, so that we could get a good sample of women with similar labor patterns," said Michael Haydon, M.D., one of the study's authors.

The study was a double-masked trial in which 270 nulliparous women were randomized to one of three groups. Initially, an intrathecal dose of 2 mg bupivicaine/20mcg fentanyl was given followed by maintenance epidural infusion 0.1% bupivicaine/2 mcg/ml fentanyl. Group 1 CEI background only (10 mls/hr); Group 2 CEI+PCEA(CEI at 10 ml/hr plus PCEA 10 ml, 20 min lockout; Group 3 PCEA only (PCEA 10 ml, 20 min lockout). PCEA bolus button was given to each subject and the pump acknowledged the request regardless of group assignment. The primary outcome was dosage of local anesthetic used. Secondary outcomes include obstetric outcomes and maternal satisfaction.

The study results showed that total mg bupivicaine used was less in the PCEA only group compared to CEI; group 1 (74.9 36 mg), group 2 (95.9 52 mg), group 3 (52.8 42 mg) p<.001. No differences were seen in total time of labor; group 1 (8.4 hr), group 2 (7.9 hr), group 3 (8.0 hr) or cesarean delivery; group 1 (26/87), group 2 (23/84), and group 3 (22/85). Number of instrumented vaginal deliveries was slightly higher in subjects with a continuous background infusion; group 1 (8/87), group 2 (8/84), group 3 (3/85). Neither lower extremity strength nor urge to push were affected by method of epidural. Pain with pushing, however, was worse in PCEA only. Median satisfaction scores were similar; 0 (best)-100(worst); group 1: 0 (0-100), group 2: 0 (0-100), group 3: 0 (0-100).

The study concluded that PCEA resulted in 30 percent less analgesia being used while maintaining high maternal satisfaction. There was also a trend toward reduction in instrumented vaginal deliveries in the PCEA only group.

"Though patients in each group showed equal satisfaction, we did note that there was more pain during the final delivery stage in the PCEA group," said Haydon. "The next step is to look at shortening the lock-out intervals between doses, or having the option of administering additional analgesia during the final pushing stage."

Haydon also noted that, in future, he expects the technology to move in the direction of automated analgesia delivery in response to patient need.


'/>"/>

Contact: Vicki Bendure
vicki@bendurepr.com
202-374-9259
Society for Maternal-Fetal Medicine
Source:Eurekalert

Related medicine news :

1. Mouse Study Suggests New Clues to Celiac Disease
2. Many Breakthrough Drugs Come From Publicly Funded Research: Study
3. Johns Hopkins School of Medicine grants $5 million to study cognitive disorders
4. Removing Many Lymph Nodes in Early Breast Cancer Not Always Needed: Study
5. Study Links Brain Molecule to Risk of Major Depression
6. Processed, Fatty Foods May Dumb Down Your Kids: Study
7. Study shows delayed-enhancement MRI may predict, prevent strokes
8. Study: Consumers value safer food more than current analyses suggest
9. Hospitals Often Fail to Follow Up on Tests, Study Says
10. New study to use smart phones to track air pollution exposure
11. Daily Pill Dispensers an Asset in Homes for Elderly: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: